secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001140361-26-019295
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Q1 revenue flat at $114.5M, ASCENIV up 28%; withdraws long-term guidance
-----------------------------------------------------------------------------

- Revenue $114.5M flat YoY; ASCENIV rev $97.5M (+28%) offset by BIVIGAM -54%.
- GAAP net income $45.3M (+68%); Adjusted net income $40.7M (+22%); Adjusted EBITDA $59.7M (+24%).
- FY 2026 guidance: rev $530-560M, Adj EBITDA $265-300M; withdraws long-term guidance due to market dynamics.
- Audit committee review found no improper channel stuffing or undisclosed related-party transactions.
- Cash from ops $58M; gross margin expanded to 71% from 53% on product mix shift.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036126019295/0001140361-26-019295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036126019295/ef20072554_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-019295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer